Literature DB >> 8689940

Relative potency of mexiletine, lidocaine, and tocainide as inhibitors of rat liver CYP1A1 activity.

X Wei1, C M Loi, E J Jarvi, R E Vestal.   

Abstract

Mexiletine and tocainide are lidocaine congeners that share similar chemical structures. Clinical studies suggest that the in vivo inhibitory effect of mexiletine on the CYP1A family of isoforms is substantially greater than that of tocainide. We investigated the inhibitory property of mexiletine, lidocaine, and tocainide on the in vitro activity of the cytochrome P4501A1 (CYP1A1) isozyme in the rat. Hepatic microsomes were prepared from rat livers induced with 3-methylcholanthrene. The rate of ethoxyresorufin-O-dealkylation (EROD) was used as an index of CYP1A1 activity. Vmax and KM of the reactions were determined from Lineweaver-Burk plots. The Ki values for the inhibitors were derived from Dixon plots. Results showed that mexiletine is a competitive inhibitor, lidocaine is a mixed inhibitor, and tocainide is a noncompetitive inhibitor of EROD. The Ki values for mexiletine and tocainide were 0.30 +/- 0.02 mM and 12.4 +/- 0.7 mM, respectively. Two Ki values for lidocaine were determined. They were 0.65 +/- 0.07 mM and 4.1 +/- 1.3 mM, respectively. The relative inhibitory potency of these agents on rat CYP1A1 activity is mexiletine > lidocaine > tocainide. This difference in potency, which is most likely attributable to the change in the chemical composition in the aliphatic chain among the compounds, suggests that these compounds may be useful probes for studying the mechanism of the interaction with the active site of CYP1A1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8689940

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

2.  Preferential inhibition of CYP1A enzymes in hepatic microsomes by mexiletine.

Authors:  H Konishi; K Morita; T Minouchi; A Yamaji
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Apr-Jun       Impact factor: 2.441

Review 3.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 4.  Cytochrome P450 family 1 inhibitors and structure-activity relationships.

Authors:  Jiawang Liu; Jayalakshmi Sridhar; Maryam Foroozesh
Journal:  Molecules       Date:  2013-11-25       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.